Skip to content

LASIK iDesign vs SMILE

Visual Outcomes Comparison of LASIK Using Wavefront Optimized and SMILE

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07126756
Acronym
TG-LASIK vs SM
Enrollment
57
Registered
2025-08-17
Start date
2024-06-10
Completion date
2026-01-31
Last updated
2025-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism, Myopia

Brief summary

The study will compare the 6-month visual outcomes (i.e., visual acuity, contract sensitivity, higher order aberrations), quality of vision (i.e., double vision, glare, starburst, halos, etc.) and dry eye symptoms of patients undergoing contralateral LASIK using iDesign and SMILE surgery.

Detailed description

Both SMILE and LASIK treatments are FDA-approved and are both performed routinely as standard of care surgery in the US Military. However, there is limited literature comparing quality of vision after LASIK using iDesign and SMILE refractive surgery. Our objective is to study the 6-month visual outcomes (high and 5% low contrast visual acuity, refractive error, higher order aberrations) and subject reported quality of vision (i.e., double vision, glare, starburst, halos, etc.) and dry eye symptoms using the PROWL and SPEED questionnaires following contralateral LASIK using iDesign and SMILE surgery. This is a prospective randomized contralateral study, including 57 subjects. Once consented to participate in the study, subjects will have a comprehensive ocular examination to determine eligibility to undergo simultaneous SMILE surgery in one eye and LASIK using iDesign on the contralateral eye to correct myopia. Surgical treatment will be randomized so there is a 50% chance to receive SMILE on the right eye and LASIK on the contralateral eye. Subjects will receive standard of care topical ophthalmic antibiotic and steroid drops. Visual outcomes and patient self-reported symptoms will be assessed at day 1, week 2, month 1, month 3, and month 6.

Interventions

DEVICESTAR S4 IR Excimer Laser System

LASIK with iDesign

DEVICEVisuMax 400 Surgical Laser

small incision lenticule extraction technique

Sponsors

United States Army Aeromedical Research Laboratory
CollaboratorFED
59th Medical Wing
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Prospective randomized contralateral study

Eligibility

Sex/Gender
ALL
Age
21 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

1. Nearsightedness (myopia) between -2.00 diopters and -8.00 diopters 2. Have similar levels of nearsightedness in each eye (2D or less difference between eyes) 3. Less than or equal to 3.00 diopters of astigmatism 4. Total spherical equivalent (SE) of no more than -8.0 D 5. Tricare Prime/Select Beneficiary (military health insurance) 6. Residing within 60 miles radius from Lackland AFB

Exclusion criteria

1. Subjects with corneal abnormal findings including signs of keratoconus, keratoconus suspect, abnormal corneal topography, epithelial basement membrane disease, pellucid marginal degeneration, corneal degenerations, progressive and unstable myopia, irregular or unstable corneal mires on central keratometry images, and volunteers whose corneal thickness would cause anticipated treatment would violate the posterior 250 microns (um) of corneal stroma from the corneal endothelium. 2. Subjects with active collagen vascular, connective tissue, autoimmune or immunodeficiency diseases 3. Pregnant or nursing females (pregnancy test will be performed on females subjects of childbearing potential) 4. Systemic disease likely to affect wound healing, such as uncontrolled diabetes and severe atopy 5. Any ocular disease such as advanced/uncontrolled glaucoma, severe dry eye, active eye infection or inflammation, recent herpes eye infection or problems resulting from past infection. 6. 0.25 or 0.50 of manifest astigmatism in the eye randomized to SMILE 7. Taking the medication Isotretinoin (Accutane) or antimetabolites for any medical condition. 8. Potential candidate who cannot provide Informed Consent will not be allowed to participate.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Eyes With Uncorrected Visual Acuity of 20/16 or Better at 6-month Post-Op6-month Post-OpPost-operative uncorrected visual acuity of 20/16 or better measure using the ETDRS chart reported as percentage of subjects; unit = percentage eyes with Uncorrected Visual Acuity

Secondary

MeasureTime frameDescription
Difference in High Contrast Visual Acuity at 6-month Post-Op6-month Post-OpMean uncorrected high contrast visual acuity measure using the ETDRS chart measure at 6-month Post-Op; unit = LogMAR
Difference in residual Refractive Error at 6-month Post-Op6-month Post-OpResidual mean refractive error measure with phoropter at 6-month Post-Op; unit = Diopters (D)
Difference in Low Contrast Visual Acuity at 6-month Post-Op6-month Post-OpMean uncorrected low contrast visual acuity measure using the 5% ETDRS chart measure at 6-month Post-Op; unit = LogMAR
Difference in residual Higher Order Aberrations at 6-month Post-Op6-month Post-OpMean Higher Order Aberrations measure by iDesign 2.0 Refractive Studio at 6-month Post-Op; unit = root mean square
Difference in overall satisfaction questionnaire score at 6-month Post-Op6-month Post-OpMean Subject Satisfaction Score with the surgery outcome using the Patient-Reported Outcomes with LASIK Symptoms and Satisfaction (PROWL-SS) Questionnaire at 6-month Post-Op. The score ranges from 1 (completely satisfied) to 6 (completely dissatisfied). Lower value indicates higher satisfaction.
Difference in overall Dry Eye questionnaire score at 6-month Post-Op6-month Post-OpMean Standard Patient Evaluation of Eye Dryness (SPEED) Questionnaire score at 6-month Post-Op. Possible dry eye symptoms score ranges from 0 (never) to 3 (Constant). Higher value indicates worse dry eye symptoms.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026